Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML

BACKGROUND: Venetoclax monotherapy is an effective option for patients with acute myeloid leukemia (AML). Venetoclax has also been used in non-myeloablative conditioning allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk AML with a tolerable toxicity profile. However, the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xing-yu, Chen, Jia-qi, Wang, Hui, Ma, Wei, Liu, Wei-wei, Zhang, Fang-fang, Xue, Song, Dong, Lei, Liu, Ting, Zhao, Xiao-zhen, Liu, Chan-chan, Xu, Xin, He, Yang, Wang, Lei, Wang, Jian-ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851264/
https://www.ncbi.nlm.nih.gov/pubmed/36629738
http://dx.doi.org/10.1080/07853890.2022.2164610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851264/
https://www.ncbi.nlm.nih.gov/pubmed/36629738
http://dx.doi.org/10.1080/07853890.2022.2164610

Ejemplares similares